“We begin with drug-like non-natural cyclic peptides ... Target-specific oral and topical administrations are lacking.” Peptide therapeutics have expanded from metabolic diseases to oncology ...

The development of oral peptide-based drugs presents unique challenges, specifies Brittany Hayes, PhD, Highly Potent & Oncology Platform Director at CordenPharma, due to the harsh environment of the ...

At the same time, developing cyclic peptides as oral drugs has proven difficult because they are rapidly digested or poorly absorbed by the gastrointestinal tract. "Cyclic peptides are of great ...

Antimicrobial peptides (AMPs) are an ancient group ... term therapy (days to weeks), and in combination with other drugs. Modern topical calcineurin inhibitors, immunomodulators, are used in ...

"Mirror Peptides open up an unprecedented chemical space beyond what Nature provides," said Ajay Kshatriya, Chief Executive Officer of Aizen. "When configured as a targeting moiety or drug ...

GemVax revealed Tuesday that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy (PSP). PSP is a degenerative disease, not unlike Parkinson’s ...

Weight regain and worsening cardiometabolic status are real threats. Too few physicians pay notice, a new viewpoint argues.

"At the same time, expanded coverage could also increase Medicaid drug spending and put pressure on overall state budgets." Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone ...

(NASDAQ: LEXX), a global innovator in drug delivery platforms ... “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results ...